Optimized second-generation mRNA vaccine demonstrated improved protection against COVID-19 in preclinical testing — ScienceDaily
In a recent phase 2b/3 clinical trial, a third mRNA vaccine against COVID-19 — known as CVnCoV and developed by CureVac — reported approximately 48 percent efficacy against symptomatic disease.…
